🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Liquid biopsy is here to stay! Clearance of ctDNA in neoadjuvant phase is associated with improved outcomes to durva + tremlo + EV in cis-ineligible pts with MIBC # ESMO24 OncoAlert

Tracking #translocationRCC in cfDNA via plasma epigenomic profiling! Check out poster #ESMO24 by superstar tag-team ⁦Simon Garinet⁩ ⁦Karl Semaan, MD, MSc⁩ w/ ⁦Srinivas Viswanathan⁩ ⁦Sylvan Baca MD PhD (Hiring!)⁩ ⁦Toni Choueiri, MD⁩ #MattFreedman ⁦ESMO - Eur. Oncology⁩ ⁦Dana-Farber⁩

Great work by my dear Dana-Farber Lank Center for Genitourinary Oncology colleague Marc Machaalani who explored ERBB2 amplifications across different cancer types in the AACR projectGENIE presented at ESMO - Eur. Oncology !

Another work from Karl Semaan, MD, MSc —Karl is a super star MD researcher Dana-Farber Lank Center for Genitourinary Oncology ably mentored by Sylvan Baca MD PhD (Hiring!) —Karl is applying to ABIM Foundation Internal Medicine Residency —please take note programs !

1/ 🧵Excited to share our latest study published in Nature Cancer co-led with amazing co-first authors and friends Tejas Jammihal and Chris Labaki under the exceptional mentorship of Toni Choueiri, MD David Braun Sachet Ashok Shukla nature.com/articles/s4301…

Our rising star Wassim Daoud Khatoun taking the stage to discuss the association between IL7 SNP & irAE. Sky is the limit! Dana-Farber Lank Center for Genitourinary Oncology OncLive.com OncoAlert

Fantastic presentation by Dana-Farber Lank Center for Genitourinary Oncology superstar Eddy Saad about TLS detection in mRCC! Dana-Farber Eli Van Allen

Spectacular presentation from Dana-Farber Lank Center for Genitourinary Oncology superstar/computational biologist Karl Semaan, MD, MSc. First work to show longitudinal monitoring of NEPC using liquid biopsy! With super mentorship from Sylvan Baca MD PhD (Hiring!) #FreedmanLab

Outstanding presentation by our phenomenal epigenetics star Marc Eid discussing liquid biopsy epigenomic profiling of sarc #RCC! #FreedmanLab Sylvan Baca MD PhD (Hiring!) Dana-Farber Lank Center for Genitourinary Oncology OncLive.com

So proud of mentees Razane El Hajj Chehade, Karl Semaan, MD, MSc, Rashad Nawfal, MD, and Marc Eid for their fantastic talks at ASCO #GU25. Their translational projects should lead to better outcomes for patients with kidney or prostate cancer.

Incredibly honored and thrilled to have matched at my top choice BIDMC IM Residency! Beyond grateful to my amazing mentors, friends, and family who supported me every step of the way Toni Choueiri, MD Eli Van Allen David Braun Sasha Gusev Maxine Sun

I am absolutely thrilled to have matched at Brigham and Women's Medicine Residents Brigham and Women's Hospital for internal medicine residency! Incredibly grateful to my amazing mentors, colleagues, and friends who have supported me throughout this journey Sylvan Baca MD PhD (Hiring!) #MattFreedman Toni Choueiri, MD #Match2025

Brilliant Yale residents presenting their work! Talal El Zarif, MD Sanju Garimella

If you are at #AACR25 and interested in #pancreaticcancer and #liquidbiopsy, check out our poster #5926 section 32 from 2-5pm today.

At #AACR25, Dana-Farber researchers present a non-invasive method to distinguish classical vs. basal #PDAC using circulating tumor epigenomic profiles which could pave the way for more personalized treatment decisions. #PancreaticCancer #CancerResearch Karl Semaan, MD, MSc Marc Eid

Awesome work by Karl Semaan, MD, MSc Marc Eid on a circulating epigenomic assay for pancreatic adenocarcinoma! AACR #AACR25 Toni Choueiri, MD Sylvan Baca MD PhD (Hiring!)

Grateful for your unwavering support Dr. Choueiri

Great poster presentations at #AACR25 by Ze Zhang and Marc Eid on computational methods for epigenomic liquid biopsy and circulating signatures of pancreatic cancer subtypes.

🎉Huge congrats to Chris Labaki and all team for this great study! ⭐️A meta-analysis including 1,644 CUP patients shows that molecularly directed therapy (MDT) significantly improves overall (HR 0.75) and progression-free survival (HR 0.79) vs empiric treatment. 🎯Supports MDT

Pre-#ASCO25 appreciation tweet to Toni Choueiri, MD and David Braun who are always taking the time to meet and discuss projects/presentations despite very busy schedules! Looking forward to a reunion in Chicago! OncoAlert